良性前列腺增生相关下尿路症状的临床指南依从性差与不适当检测
结果显示尽管老年男性LUTS/BPH风险更高,但诊断时接受检测的可能性更低;尿常规是最常见检测但仅在不到60%的新发患者中执行,PSA检测率为15-34%。结论认为推荐检测执行不佳,提供者应更遵循AUA指南。
要点
- 老年男性LUTS/BPH风险更高但诊断时检测更少。
- 尿常规是最常见检测但执行率不足60%。
- PSA检测率各年龄组为15-34%。
核心结论
- 尽管老年男性LUTS/BPH风险更高,但诊断时接受检测的可能性更低,推荐检测执行不佳。
研究设计与样本
- 分析两个保险索赔数据库:Optum私有保险40-64岁男性每年约1,650,900人,Medicare 5%样本65岁以上男性每年约546,000人。
- 计算2004-2013年LUTS/BPH及合并膀胱癌、膀胱结石的年度患病率,并检查2009年新诊断LUTS/BPH队列的检测指南依从性。
主要发现
- LUTS/BPH患病率和发病率随年龄增加,但评估检测变得不常见。
- 尿常规是最常见检测类型,但在新发患者中执行率低于60%。
- 血清PSA是第二常见检测,各年龄组范围为15-34%。
- 合并膀胱癌患病率范围为0-4%且随年龄增加,膀胱结石患病率范围为1-2%未随年龄增加。
临床怎么用
- 提供者在评估LUTS/BPH患者时应更认知AUA指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Urological Association makes recommendations for evaluation and testing for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) to help primary care providers and specialists identify LUTS/BPH and harmful related conditions including urinary retention and prostate or bladder cancer. Our understanding of provider adherence to these Guidelines is limited to single-site or nonrepresentative settings. METHODS: We analyzed two insurance claims databases: the Optum® de-identified Clinformatics® Data Mart database for privately insured males aged 40-64 years (N ≈ 1,650,900 annually) and the Medicare 5% Sample for males aged ≥65 years (N ≈ 546,000 annually). We calculated the annual prevalence of LUTS/BPH and comorbid bladder cancer and bladder stones from 2004 to 2013. We additionally examined LUTS/BPH incidence and adherence to testing guidelines in a cohort of men newly diagnosed with LUTS/BPH in 2009. RESULTS: While LUTS/BPH prevalence and incidence increased with increasing age, evaluation testing became less common. Urinalysis was the most common testing type but was performed in <60% of incident patients. Serum prostate-specific antigen (PSA) was the second most common test across age groups (range: 15-34%). Prevalence of comorbid bladder cancer (range: 0-4%), but not bladder stones (range: 1-2%), increased with increasing age. CONCLUSIONS: Although older men were at greater risk of LUTS/BPH than younger men, they were less likely to undergo testing at diagnosis. Recommended testing with urinalysis was poor despite higher prevalence of bladder cancer in older men and a standard recommendation for urinalysis since 1994. Providers should be more cognizant of AUA Guidelines when assessing LUTS/BPH patients.
引用
- Welliver C, Feinstein L, Ward JB, et al. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021. PMID: 34545201. doi:10.1038/s41391-021-00435-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。